Completed PHASE1 INTERVENTIONAL 3-arm NCT01525394

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Sponsor: Eisai Inc.

Conditions Lymphomas Refractory Solid Tumors

Interventions Lenvatinib Moxifloxacin 400 mg Placebos (matched to 4 mg and 10 mg lenvatinib capsules).

Updated 7 times since 2017 Last updated: Jun 20, 2023 Started: Dec 31, 2010 Primary completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01525394, this PHASE1 trial focuses on Lymphomas and Refractory Solid Tumors and remains completed. Sponsored by Eisai Inc., it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tacoma, United States